Working… Menu

Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) (CAPRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02565992
Recruitment Status : Completed
First Posted : October 1, 2015
Last Update Posted : January 18, 2020
Information provided by (Responsible Party):

Brief Summary:
This study will employ a phase Ib design using the established dose of CAVATAK with pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be important in amplifying the T-cell potentiating effects of pembrolizumab.

Condition or disease Intervention/treatment Phase
Melanoma Biological: CAVATAK Drug: Pembrolizumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)
Actual Study Start Date : December 17, 2015
Actual Primary Completion Date : November 4, 2019
Actual Study Completion Date : November 4, 2019

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Melanoma
MedlinePlus related topics: Melanoma

Arm Intervention/treatment
Experimental: CAVATAK and pembrolizumab
Intratumoral CAVATAK administration on trial days 1, 3, 5 and 8 and at 3-weekly intervals up to a maximum of 19 total with intravenous pembrolizumab (2 mg/kg solution) starting on day 8 and continuing every 3 weeks, up to 2 years.
Biological: CAVATAK
Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
Other Name: Coxsackievirus A21, CVA21

Drug: Pembrolizumab
Intravenous pembrolizumab at 2 mg/kg solution.

Primary Outcome Measures :
  1. The incidence of dose-limiting toxicities (DLT) of intravenous pembrolizumab in combination with intratumoral CAVATAK will be assessed using CTCAE v. 4.0. [ Time Frame: Up to 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects with metastatic or unresectable stage IIIb/c of IV melanoma for whom treatment with pembrolizumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection.
  • At least one tumor must qualify to be an index lesion for modified WHO criteria.
  • Subjects must have adequate hematologic, hepatic and renal function.
  • ECOG performance status of 0 or 1.
  • Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

  • Ocular primary tumors.
  • Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.
  • Tumors lying in mucosal regions or close to an airway, major blood vessel or spinal cord.
  • Subjects with active, known or suspected autoimmune or immunosuppressive disease.
  • Subjects previously treated with CVA21.
  • Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.
  • Subject has received chemotherapy within the last 4 weeks prior to first treatment.
  • Clinically significant cardiovascular disease.
  • Females of childbearing potential must have negative serum or urine pregnancy test.
  • Subjects requiring or using other investigational agents while on treatment in this trial.
  • History of other malignancy within the last 3 years (with exceptions).
  • Active infection requiring systemic therapy.
  • Known history of HIV disease, active hepatitis B or hepatitis C.
  • History or evidence of other clinically significant disorders that would pose a risk to subject safety.
  • Inability to give informed consent and comply with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02565992

Layout table for location information
United States, California
John Wayne Cancer Institute
Santa Monica, California, United States, 90404
United States, New Jersey
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, United States, 08901
United States, Ohio
Gabrail Cancer Center Research
Canton, Ohio, United States, 44718
Sponsors and Collaborators
Layout table for additonal information
Responsible Party: Viralytics Identifier: NCT02565992    
Other Study ID Numbers: V937-007
VLA-011 ( Other Identifier: Viralytics Study ID )
First Posted: October 1, 2015    Key Record Dates
Last Update Posted: January 18, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:
Keywords provided by Viralytics:
Coxsackievirus A21
checkpoint inhibitor
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Immunological
Antineoplastic Agents